Phase III trial of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (MAYO) vs. weekly oxaliplatin (OXA) plus high dose 24h 5-FU infusion/FA in patients with advanced colorectal cancer (CRC)Axel Grothey, Hans‐Joachim Schmoll, T. Buechele et al.|European Journal of Cancer|2001Cited by 57
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: Petrarca—A phase II trial of the German AIO.Ralf‐Dieter Hofheinz, Salah‐Eddin Al‐Batran, K Borchert et al.|Journal of Clinical Oncology|2017Cited by 12
Quality of life maintained on the ziv-aflibercept/FOLFIRI regimen: Third interim analysis of the global aflibercept safety and HR-QOL program.Julien Taı̈eb, Alberto F. Sobrero, Roberto Bordonaro et al.|Journal of Clinical Oncology|2014Cited by 1
Ziv-aflibercept in combination with FOLFIRI for the second-line treatment of patients with metastatic colorectal cancer: Third interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies).Roberto Bordonaro, Julien Taı̈eb, Alberto F. Sobrero et al.|Journal of Clinical Oncology|2014Cited by 0